Literature DB >> 20807983

Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Thorsten Zenz, Daniel Mertens, Stephan Stilgenbauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20807983      PMCID： PMC2930941          DOI： 10.3324/haematol.2010.027151

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

Authors:  P Dreger; P Corradini; E Kimby; M Michallet; D Milligan; J Schetelig; W Wiktor-Jedrzejczak; D Niederwieser; M Hallek; E Montserrat
Journal:  Leukemia       Date:  2006-11-16       Impact factor: 11.528

2.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

3.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance.

Authors:  T Zenz; S Häbe; T Denzel; D Winkler; H Döhner; S Stilgenbauer
Journal:  Leukemia       Date:  2008-05-15       Impact factor: 11.528

Review 5.  How I treat refractory CLL.

Authors:  Emili Montserrat; Carol Moreno; Jordi Esteve; Alvaro Urbano-Ispizua; Eva Giné; Francesc Bosch
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

6.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

7.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

Authors:  Kostas Stamatopoulos; Chrysoula Belessi; Carol Moreno; Myriam Boudjograh; Giuseppe Guida; Tatjana Smilevska; Lynda Belhoul; Stefania Stella; Niki Stavroyianni; Marta Crespo; Anastasia Hadzidimitriou; Laurent Sutton; Francesc Bosch; Nikolaos Laoutaris; Achilles Anagnostopoulos; Emili Montserrat; Athanasios Fassas; Guillaume Dighiero; Federico Caligaris-Cappio; Hélène Merle-Béral; Paolo Ghia; Frédéric Davi
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

8.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

Authors:  Michael R Grever; David M Lucas; Gordon W Dewald; Donna S Neuberg; John C Reed; Shinichi Kitada; Ian W Flinn; Martin S Tallman; Frederick R Appelbaum; Richard A Larson; Elisabeth Paietta; Diane F Jelinek; John G Gribben; John C Byrd
Journal:  J Clin Oncol       Date:  2007-02-05       Impact factor: 44.544

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

Authors:  O G Best; A C Gardiner; Z A Davis; I Tracy; R E Ibbotson; A Majid; M J S Dyer; D G Oscier
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528
View more
  1 in total

Review 1.  Overview of recent developments in chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Kanti R Rai
Journal:  South Asian J Cancer       Date:  2012-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.